IL159714A0 - 5-cnac as oral delivery agent for parathyroid hormone fragments - Google Patents

5-cnac as oral delivery agent for parathyroid hormone fragments

Info

Publication number
IL159714A0
IL159714A0 IL15971402A IL15971402A IL159714A0 IL 159714 A0 IL159714 A0 IL 159714A0 IL 15971402 A IL15971402 A IL 15971402A IL 15971402 A IL15971402 A IL 15971402A IL 159714 A0 IL159714 A0 IL 159714A0
Authority
IL
Israel
Prior art keywords
parathyroid hormone
oral delivery
cnac
delivery agent
hormone fragments
Prior art date
Application number
IL15971402A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL159714A0 publication Critical patent/IL159714A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL15971402A 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments IL159714A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (1)

Publication Number Publication Date
IL159714A0 true IL159714A0 (en) 2004-06-20

Family

ID=23214149

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15971402A IL159714A0 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments
IL159714A IL159714A (en) 2001-08-17 2004-01-05 Pharmaceutical composition for oral delivery comprising a fragment of parathyroid hormone and 5-cnac

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL159714A IL159714A (en) 2001-08-17 2004-01-05 Pharmaceutical composition for oral delivery comprising a fragment of parathyroid hormone and 5-cnac

Country Status (26)

Country Link
US (4) US20040242478A1 (pt)
EP (1) EP1420827B8 (pt)
JP (2) JP4959917B2 (pt)
KR (1) KR20040030120A (pt)
CN (1) CN1279981C (pt)
AT (1) ATE443527T1 (pt)
AU (1) AU2002333443C1 (pt)
BR (1) BRPI0211932B1 (pt)
CA (1) CA2453646C (pt)
CO (1) CO5560586A2 (pt)
CY (1) CY1109661T1 (pt)
DE (1) DE60233803D1 (pt)
DK (1) DK1420827T3 (pt)
EC (1) ECSP044961A (pt)
ES (1) ES2333587T3 (pt)
HU (1) HUP0401441A3 (pt)
IL (2) IL159714A0 (pt)
MX (1) MXPA04001418A (pt)
NO (1) NO328069B1 (pt)
NZ (1) NZ531018A (pt)
PL (1) PL210258B1 (pt)
PT (1) PT1420827E (pt)
RU (1) RU2322256C2 (pt)
SI (1) SI1420827T1 (pt)
WO (1) WO2003015822A1 (pt)
ZA (1) ZA200400242B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040007617A (ko) * 2001-06-01 2004-01-24 노파르티스 아게 부갑상선 호르몬 및 칼시토닌의 경구 투여
CA2453646C (en) * 2001-08-17 2008-09-30 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
WO2003086408A1 (en) * 2002-04-10 2003-10-23 University Of Virginia Patent Foundation Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TWI343816B (en) 2003-07-23 2011-06-21 Novartis Ag Use of calcitonin in osteoarthritis
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
CA2607901C (en) * 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
AR058053A1 (es) 2005-09-19 2008-01-23 Toole Doris C O Formas cristalinas polimorficas de la sal de di- sodio del acido n- (5 -clorosaliciloil)-8- aminocaprilico
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
AU2006315132A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP2059260B1 (en) * 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
CA2679782C (en) 2007-03-02 2015-02-17 Novartis Ag Oral administration of a calcitonin
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
US20180050096A1 (en) * 2015-02-09 2018-02-22 Entera Bio Ltd. Treatment of hypoparathyroidism
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
CZ286632B6 (cs) * 1992-09-29 2000-05-17 Inhale Therapeutic Systems Farmaceutický prostředek
ATE383169T1 (de) * 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1175444B1 (en) * 1998-11-25 2008-01-23 The General Hospital Corporation Amino-terminal modified parathyroid hormone (pth) analogs
ATE288415T1 (de) * 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
CA2402719C (en) * 2000-03-21 2012-03-20 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
KR20040007617A (ko) * 2001-06-01 2004-01-24 노파르티스 아게 부갑상선 호르몬 및 칼시토닌의 경구 투여
CA2453646C (en) * 2001-08-17 2008-09-30 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
BRPI0412458A (pt) * 2003-07-11 2006-10-17 Novartis Ag composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada

Also Published As

Publication number Publication date
CA2453646C (en) 2008-09-30
BRPI0211932B1 (pt) 2016-12-06
KR20040030120A (ko) 2004-04-08
US20060217313A1 (en) 2006-09-28
NO20040598L (no) 2004-02-10
US9272040B2 (en) 2016-03-01
CA2453646A1 (en) 2003-02-27
PT1420827E (pt) 2009-12-15
CO5560586A2 (es) 2005-09-30
PL210258B1 (pl) 2011-12-30
CY1109661T1 (el) 2014-08-13
AU2002333443B2 (en) 2006-06-29
AU2002333443C1 (en) 2009-10-08
RU2322256C2 (ru) 2008-04-20
JP4959917B2 (ja) 2012-06-27
JP2009242410A (ja) 2009-10-22
BR0211932A (pt) 2004-10-26
CN1543357A (zh) 2004-11-03
US20120088725A1 (en) 2012-04-12
EP1420827B8 (en) 2009-12-23
RU2004107899A (ru) 2005-05-10
ECSP044961A (es) 2004-03-23
MXPA04001418A (es) 2004-05-27
WO2003015822A1 (en) 2003-02-27
HUP0401441A2 (hu) 2004-12-28
DE60233803D1 (de) 2009-11-05
EP1420827B1 (en) 2009-09-23
US20040242478A1 (en) 2004-12-02
ATE443527T1 (de) 2009-10-15
IL159714A (en) 2010-12-30
US20090264367A1 (en) 2009-10-22
CN1279981C (zh) 2006-10-18
PL365388A1 (en) 2005-01-10
EP1420827A1 (en) 2004-05-26
HUP0401441A3 (en) 2012-09-28
NZ531018A (en) 2006-03-31
SI1420827T1 (sl) 2010-01-29
ES2333587T3 (es) 2010-02-24
DK1420827T3 (da) 2009-12-21
NO328069B1 (no) 2009-11-23
JP2005501852A (ja) 2005-01-20
ZA200400242B (en) 2004-11-18

Similar Documents

Publication Publication Date Title
IL159714A0 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
MXPA06012980A (es) Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
IL159996A0 (en) Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
WO2003047504A3 (en) Prevention and treatment of androgen-deprivation induced osteoporosis
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
WO2002041837A3 (en) Treatment of mucositis
FR06C0032I1 (pt)
GT199700009AA (es) Terapia combinada para la osteoporosis
IL158777A0 (en) Orally administering parathyroid hormone and calcitonin
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
PL370361A1 (en) Alkyl urea retinoid agonists i
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
PL370459A1 (en) Substituted urea retinoid agonists ii
AU2003286617A8 (en) Calcitonin drug-oligomer conjugates, and uses thereof
MXPA05000978A (es) Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas.
MXPA03006157A (es) Metodo de terapia de reemplazo de hormona y su forma de administracion.
HUP0204258A3 (en) Use of vitamin d-derivatives for preparation of pharmaceutical compositions useful in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
IL125983A0 (en) Pharmaceutical composition comprising factor xiiia
EP1408043A8 (en) 2''oxo-voruscharin and analogues thereof
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture